1. Home
  2. TSHA vs POLE Comparison

TSHA vs POLE Comparison

Compare TSHA & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSHA
  • POLE
  • Stock Information
  • Founded
  • TSHA 2019
  • POLE 2024
  • Country
  • TSHA United States
  • POLE United States
  • Employees
  • TSHA N/A
  • POLE N/A
  • Industry
  • TSHA Biotechnology: Pharmaceutical Preparations
  • POLE
  • Sector
  • TSHA Health Care
  • POLE
  • Exchange
  • TSHA Nasdaq
  • POLE NYSE
  • Market Cap
  • TSHA 313.6M
  • POLE 294.2M
  • IPO Year
  • TSHA 2020
  • POLE 2024
  • Fundamental
  • Price
  • TSHA $1.53
  • POLE $10.02
  • Analyst Decision
  • TSHA Strong Buy
  • POLE
  • Analyst Count
  • TSHA 8
  • POLE 0
  • Target Price
  • TSHA $6.63
  • POLE N/A
  • AVG Volume (30 Days)
  • TSHA 2.3M
  • POLE 7.3K
  • Earning Date
  • TSHA 11-13-2024
  • POLE 01-01-0001
  • Dividend Yield
  • TSHA N/A
  • POLE N/A
  • EPS Growth
  • TSHA N/A
  • POLE N/A
  • EPS
  • TSHA N/A
  • POLE N/A
  • Revenue
  • TSHA $9,915,000.00
  • POLE N/A
  • Revenue This Year
  • TSHA N/A
  • POLE N/A
  • Revenue Next Year
  • TSHA N/A
  • POLE N/A
  • P/E Ratio
  • TSHA N/A
  • POLE N/A
  • Revenue Growth
  • TSHA N/A
  • POLE N/A
  • 52 Week Low
  • TSHA $1.19
  • POLE $9.94
  • 52 Week High
  • TSHA $4.32
  • POLE $11.05
  • Technical
  • Relative Strength Index (RSI)
  • TSHA 34.16
  • POLE N/A
  • Support Level
  • TSHA $1.56
  • POLE N/A
  • Resistance Level
  • TSHA $1.75
  • POLE N/A
  • Average True Range (ATR)
  • TSHA 0.16
  • POLE 0.00
  • MACD
  • TSHA -0.02
  • POLE 0.00
  • Stochastic Oscillator
  • TSHA 3.57
  • POLE 0.00

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

Share on Social Networks: